Concept Medical Initiates Global STARS DAPT Trial for Polymer-Free Drug-Eluting Stent in STEMI Patients
核心洞察
Concept Medical has enrolled the first four patients in the STARS DAPT randomized controlled trial at University Hospital of Zurich (搜索), evaluating their polymer-free Abluminus np (搜索) drug-eluting stent for STEMI (搜索) treatment.
The international trial will enroll 350 STEMI (搜索) patients to compare shortened dual antiplatelet therapy versus conventional 6-12 month treatment, with co-primary endpoints of major adverse cardiac events and bleeding complications at 12 months.
The Abluminus np (搜索) stent features proprietary Nanoactive technology delivering sub-micron sirolimus particles without polymers, potentially enabling faster vessel healing and reduced antiplatelet therapy duration.
Concept Medical Inc (搜索). has successfully enrolled the first patients in its pivotal STARS DAPT randomized controlled trial, marking a significant advancement in the evaluation of polymer-free drug-eluting stent technology for treating ST-segment elevation myocardial infarction (搜索) (STEMI (搜索)) patients. The first four patients were enrolled by Professor Barbara Stähli and her team at the University Hospital of Zurich (搜索) in Switzerland.
Trial Design and Objectives
STARS DAPT (ST-Segment Elevation Myocardial InfArction (搜索) treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2y12 inhibitor (搜索)-based Single Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional Dual AntiPlatelet Therapy) is an investigator-initiated, prospective, multicentre, international, open-label, randomized controlled pilot study. The trial will enroll 350 all-comer subjects with STEMI (搜索) undergoing primary percutaneous coronary intervention (PCI) with the Abluminus np (搜索) stent.
The study aims to evaluate the difference between a P2Y12 receptor (搜索) inhibitor-based single antiplatelet therapy (SAPT) regimen after a short period of dual antiplatelet therapy (DAPT) versus conventional 6 or 12 months of DAPT. The co-primary endpoints at 12 months are major adverse cardiac and cerebrovascular events and major bleeding complications.
Leadership and Clinical Rationale
The randomized controlled trial is led by Principal Investigator PD Dr. Juan F. Iglesias from Geneva University Hospitals (搜索) and University of Geneva, Switzerland. Dr. Iglesias emphasized the clinical challenge addressed by the trial: "Patients with acute STEMI (搜索) represent a particularly challenging population, characterized by a dual risk profile: a high risk of ischemic events driven by a heightened prothrombotic and proinflammatory state, and an increased risk of bleeding complications associated with the use of potent antithrombotic therapies during management."
He noted that achieving an optimal balance between preventing acute thrombotic events and minimizing major bleeding remains a persistent challenge and an important unmet need in routine clinical practice.
Abluminus np Technology
The Abluminus np (搜索) drug-eluting stent utilizes Concept Medical's proprietary Nanoactive technology to deliver polymer-free sub-micron particles of sirolimus encapsulated in a biocompatible phospholipid carrier. This design ensures deep penetration into the vessel wall along with faster endothelialization. The stent features polymer-free fusion coating with sirolimus drug coated on the abluminal surface and edges.
According to the company, newer generation polymer-free DES like the Abluminus np (搜索) with thin struts, fusion and abluminal coating of sirolimus aids in natural vascular healing of the arteries, faster re-endothelialization and mitigating chronic inflammation, which permits the possibility of potentially shortening the DAPT requirement.
Clinical Development Path
Abluminus np (搜索) has already been studied in single-arm Indian registries with promising safety and efficacy results, making STARS DAPT the first randomized evaluation of this technology. The stent has also received CE mark approval in Europe.
Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, explained the rationale behind the technology: "While contemporary drug-eluting stents have achieved excellent outcomes, challenges such as polymer-related inflammation, late catch-up, and the need for prolonged dual antiplatelet therapy persist. Abluminus np (搜索) was designed as a polymer-free, sub-micron sirolimus delivery platform to enable more uniform drug distribution across the diseased vessel, extending beyond the stent struts to the stent edges and adjacent vessel segments."
Clinical Impact Potential
Dr. Iglesias noted that recent advances in polymer-free DES technology may facilitate the adoption of novel antiplatelet strategies aimed at reducing bleeding risk while preserving ischemic protection after primary PCI. "STARS DAPT is the first RCT designed to evaluate the non-inferiority of a P2Y12 inhibitor (搜索)–based SAPT strategy following a very short course of DAPT, compared with the current standard of care of 12-month DAPT, with respect to both major ischemic and bleeding outcomes at one year after primary PCI using the Abluminus np (搜索) DES."
The results of the STARS DAPT trial are expected to provide important insights into the optimal antiplatelet regimen after primary PCI and have the potential to meaningfully improve STEMI (搜索) care, particularly for patients at increased bleeding risk.